OXFORD BIOMEDICA LS-,50/ GB00BDFBVT43 /
| 14/11/2024 07:47:51 | Chg. -0.020 | Volume | Bid07:47:51 | Ask07:47:51 | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 4.860EUR | -0.41% | - Turnover: - |
4.860Bid Size: - | 5.200Ask Size: - | 399.03 mill.EUR | - | - |
Business description
Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research, development and manufacture.
Management board & Supervisory board
| CEO |
|---|
| John Dawson |
| Management board |
| Stuart Paynter, Helen Stephenson-Ellis, James Miskin, Jason Slingsby, Kyriacos Mitrophanous, Matthew Treagus, Natalie Walter, Nick Page |
| Supervisory board |
| Dr. Roch Doliveux, Dr. Michael Hayden, Dr. Sam Rasty, Heather Preston, John Dawson, Prof. Dame Kay Davies, Robert Ghenchev, Stuart Henderson, Stuart Paynter |
Company data
| Name: | Oxford BioMedica plc |
| Address: | Windrush Court, Transport Way,UK-Oxford OX4 6LT |
| Phone: | +44-1865-783-000 |
| Fax: | +44-1865-783-001 |
| E-mail: | enquiries@oxfordbiom...a.co.uk enquiries@oxfordbiomedica.co.uk |
| Internet: | https://www.oxb.com/ |
| Industry: | Healthcare |
| Sector: | Pharmaceutical Industry |
| Sub sector: | Pharmaceuticals |
| End of financial year: | 31/12 |
| Free Float: | 50.20% |
| IPO date: | - |
Investor relations
| Name: | Catherine Isted |
| IR phone: | - |
| IR Fax: | - |
| IR e-mail: | investor-relations@o...a.co.uk investor-relations@oxfordbiomedica.co.uk |
